Radimmune Therapeutics

About:

Radimmune Therapeutics is an early stage biotechnology company that pioneers innovative therapies.

Website: http://radimmune.com

Description:

Radimmune Therapeutics is an early-stage biotechnology company that pioneers innovative therapies. It develops antibody-targeted radiation therapeutics, also known as radioimmunotherapy and liquid radiation. An alpha-emitting and/or beta-emitting radioisotope is guided to a universal target antigen. Radimmune has developed proprietary antibodies targeting extracellular accumulations of, normally, intracellular substances. Since its inception, the Radimmune Therapeutics has been driven by the belief that additional tools are needed for the fight against cancer. To that end, Radimmune Therapeutics has developed proprietary technology and platform focused on the most challenging to treat cancers. It is based in Burlingame, California.

Total Funding Amount:

$13.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Burlingame, California, United States

Founded Date:

2016-01-01

Contact Email:

inquiry(AT)radimmune.com

Founders:

David Rickles, Josh Becker

Number of Employees:

1-10

Last Funding Date:

2019-08-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai